Clinical Trial

5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this study, the investigators aim to investigate the efficacy and safety of 5 years of adjuvant imatinib treatment in patients with tumor rupture defined by Nishida classification or those with a tumor size 10cm or larger and a mitotic index of 10/50HPFs or higher.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-05-18; most recent amendment 2025-08-05.
Status change: Not Yet Recruiting → Recruiting 2022-12-22
Trial Details
NCT Number NCT05385549
Lead Sponsor Asan Medical Center
Conditions Gastrointestinal Stromal Tumors
Enrollment 35 participants
Start Date 2022-09-07
Primary Completion 2030-04-30 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-08